CONMED (CNMD) Stock Forecast, Price Target & Predictions
CNMD Stock Forecast
CONMED stock forecast is as follows: an average price target of $96.00 (represents a 28.15% upside from CNMD’s last price of $74.91) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CNMD Price Target
The average price target for CONMED (CNMD) is $96.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $97.00 to $95.00. This represents a potential 28.15% upside from CNMD's last price of $74.91.
CNMD Analyst Ratings
According to 3 Wall Street analysts, CONMED's rating consensus is 'Buy'. The analyst rating breakdown for CNMD stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
CONMED Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 04, 2024 | Mike Matson | Needham | - | - | 45.67% | 29.49% |
| Apr 25, 2024 | Matt O\'Brien | Piper Sandler | - | - | 47.65% | 26.82% |
| Apr 25, 2024 | Mike Matson | Needham | - | - | 52.84% | 42.84% |
| Oct 26, 2022 | Matt O'Brien | Piper Sandler | - | - | 29.51% | 44.17% |
The latest CONMED stock forecast, released on Oct 04, 2024 by Mike Matson from Needham, set a price target of $97.00, which represents a 45.67% increase from the stock price at the time of the forecast ($66.59), and a 29.49% increase from CNMD last price ($74.91).
CONMED Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $97.00 | $99.67 |
| Last Closing Price | $74.91 | $74.91 | $74.91 |
| Upside/Downside | -100.00% | 29.49% | 33.05% |
In the current month, the average price target of CONMED stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CONMED's last price of $74.91. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 04, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Oct 04, 2024 | Wells Fargo | Buy | Buy | Hold |
| Oct 04, 2024 | Needham | Buy | Buy | Hold |
| Aug 01, 2024 | Wells Fargo | Buy | Buy | Hold |
| Apr 25, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 25, 2024 | Needham | Buy | Buy | Hold |
| Feb 01, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Feb 01, 2024 | Needham | Buy | Buy | Hold |
| Apr 27, 2023 | Needham | Buy | Buy | Hold |
| Apr 27, 2023 | Piper Sandler | Overweight | Overweight | Hold |
CONMED's last stock rating was published by Piper Sandler on Oct 04, 2024. The company gave CNMD a "Underperform" rating, the same as its previous rate.
CONMED Financial Forecast
CONMED Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $327.05M | - | $317.65M | $295.47M | $250.87M | $275.09M | $277.19M | $242.33M | $273.97M | $248.83M | $255.16M | $232.68M | $252.83M | $237.84M |
| Avg Forecast | $432.70M | $402.10M | $420.50M | $393.80M | $397.34M | $368.63M | $386.01M | $361.40M | $366.48M | $340.70M | $356.72M | $334.92M | $340.99M | $317.78M | $334.39M | $306.75M | $332.21M | $301.42M | $306.15M | $266.63M | $302.48M | $280.83M | $275.75M | $235.77M | $275.82M | $255.23M | $248.47M | $216.77M | $262.90M | $205.92M |
| High Forecast | $436.17M | $405.32M | $423.87M | $396.95M | $400.52M | $371.58M | $389.10M | $364.29M | $369.41M | $343.43M | $359.57M | $338.67M | $342.46M | $318.26M | $334.39M | $306.75M | $335.16M | $303.70M | $308.61M | $268.77M | $304.90M | $280.83M | $275.75M | $235.77M | $275.82M | $255.23M | $248.47M | $216.77M | $262.90M | $205.92M |
| Low Forecast | $428.02M | $397.75M | $415.95M | $389.54M | $393.04M | $364.64M | $381.83M | $357.49M | $362.51M | $337.01M | $352.86M | $329.75M | $338.78M | $317.31M | $334.39M | $306.75M | $331.27M | $297.71M | $302.84M | $263.75M | $299.21M | $280.83M | $275.75M | $235.77M | $275.82M | $255.23M | $248.47M | $216.77M | $262.90M | $205.92M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | - | 1.04% | 1.11% | 0.83% | 0.98% | 1.01% | 1.03% | 0.99% | 0.97% | 1.03% | 1.07% | 0.96% | 1.15% |
CONMED's average Quarter revenue forecast for Mar 24 based on 3 analysts is $306.75M, with a low forecast of $306.75M, and a high forecast of $306.75M. CNMD's average Quarter revenue forecast represents a -6.21% decrease compared to the company's last Quarter revenue of $327.05M (Dec 23).
CONMED EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $60.97M | - | $27.42M | $12.70M | $-1.09M | $24.25M | $-87.55M | $22.44M | $54.69M | $42.79M | $43.49M | $38.36M | $42.65M | $47.26M |
| Avg Forecast | $49.63M | $46.12M | $48.23M | $45.17M | $45.57M | $42.28M | $44.27M | $41.45M | $42.03M | $39.08M | $40.91M | $38.41M | $39.11M | $36.45M | $38.35M | $47.60M | $38.10M | $34.57M | $35.11M | $43.27M | $57.83M | $19.35M | $19.00M | $34.21M | $19.00M | $17.58M | $17.12M | $23.97M | $18.11M | $14.19M |
| High Forecast | $50.03M | $46.49M | $48.61M | $45.53M | $45.94M | $42.62M | $44.63M | $41.78M | $42.37M | $39.39M | $41.24M | $38.84M | $39.28M | $36.50M | $38.35M | $57.12M | $38.44M | $34.83M | $35.40M | $51.93M | $69.39M | $19.35M | $19.00M | $41.05M | $19.00M | $17.58M | $17.12M | $28.77M | $18.11M | $14.19M |
| Low Forecast | $49.09M | $45.62M | $47.71M | $44.68M | $45.08M | $41.82M | $43.79M | $41.00M | $41.58M | $38.65M | $40.47M | $37.82M | $38.86M | $36.39M | $38.35M | $38.08M | $37.99M | $34.14M | $34.73M | $34.62M | $46.26M | $19.35M | $19.00M | $27.37M | $19.00M | $17.58M | $17.12M | $19.18M | $18.11M | $14.19M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.60% | - | 0.78% | 0.29% | -0.02% | 1.25% | -4.61% | 0.66% | 2.88% | 2.43% | 2.54% | 1.60% | 2.35% | 3.33% |
3 analysts predict CNMD's average Quarter EBITDA for Mar 24 to be $47.60M, with a high of $57.12M and a low of $38.08M. This is -21.93% lower than CONMED's previous annual EBITDA (Dec 23) of $60.97M.
CONMED Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $33.07M | - | $13.73M | $1.82M | $26.58M | $46.15M | $-168.29M | $14.97M | $24.44M | $14.95M | $13.29M | $9.86M | $24.14M | $6.85M |
| Avg Forecast | - | - | - | - | $52.09M | $42.98M | $42.91M | $36.04M | $42.93M | $37.09M | $37.65M | $32.56M | $37.53M | $31.83M | $28.31M | $18.15M | $34.57M | $26.10M | $24.70M | $16.50M | $25.84M | $23.39M | $23.47M | $13.04M | $31.99M | $23.32M | $19.24M | $6.16M | $23.81M | $7.10M |
| High Forecast | - | - | - | - | $52.63M | $43.42M | $43.36M | $36.42M | $43.38M | $37.47M | $38.04M | $37.57M | $37.92M | $32.36M | $28.31M | $21.78M | $34.88M | $26.41M | $24.96M | $19.80M | $31.01M | $23.39M | $23.47M | $15.65M | $31.99M | $23.32M | $19.24M | $7.39M | $23.81M | $7.10M |
| Low Forecast | - | - | - | - | $51.36M | $42.37M | $42.31M | $35.53M | $42.33M | $36.56M | $37.12M | $27.87M | $37.00M | $31.30M | $28.31M | $14.52M | $34.26M | $25.78M | $24.35M | $13.20M | $20.68M | $23.39M | $23.47M | $10.43M | $31.99M | $23.32M | $19.24M | $4.93M | $23.81M | $7.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | - | 0.56% | 0.11% | 1.03% | 1.97% | -7.17% | 1.15% | 0.76% | 0.64% | 0.69% | 1.60% | 1.01% | 0.96% |
CONMED's average Quarter net income forecast for Mar 24 is $18.15M, with a range of $14.52M to $21.78M. CNMD's average Quarter net income forecast represents a -45.12% decrease compared to the company's last Quarter net income of $33.07M (Dec 23).
CONMED SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $127.33M | - | $129.70M | $130.08M | $120.74M | $114.60M | $115.83M | $102.88M | $107.28M | $104.74M | $104.40M | $98.34M | $99.10M | $94.38M |
| Avg Forecast | $178.92M | $166.27M | $173.88M | $162.84M | $164.30M | $152.43M | $159.61M | $149.44M | $151.54M | $140.88M | $147.50M | $138.49M | $141.00M | $131.40M | $138.27M | $124.68M | $137.37M | $124.64M | $126.59M | $113.35M | $113.42M | $116.12M | $114.02M | $89.60M | $114.05M | $105.54M | $102.74M | $61.46M | $108.71M | $85.15M |
| High Forecast | $180.35M | $167.60M | $175.27M | $164.14M | $165.62M | $153.65M | $160.89M | $150.63M | $152.75M | $142.01M | $148.68M | $140.04M | $141.60M | $131.60M | $138.27M | $149.62M | $138.59M | $125.58M | $127.61M | $136.01M | $136.11M | $116.12M | $114.02M | $107.52M | $114.05M | $105.54M | $102.74M | $73.75M | $108.71M | $85.15M |
| Low Forecast | $176.98M | $164.47M | $171.99M | $161.07M | $162.52M | $150.78M | $157.89M | $147.82M | $149.90M | $139.35M | $145.91M | $136.35M | $140.08M | $131.21M | $138.27M | $99.74M | $136.98M | $123.10M | $125.22M | $90.68M | $90.74M | $116.12M | $114.02M | $71.68M | $114.05M | $105.54M | $102.74M | $49.17M | $108.71M | $85.15M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | - | 1.02% | 1.15% | 1.06% | 0.99% | 1.02% | 1.15% | 0.94% | 0.99% | 1.02% | 1.60% | 0.91% | 1.11% |
CONMED's average Quarter SG&A projection for Mar 24 is $124.68M, based on 3 Wall Street analysts, with a range of $99.74M to $149.62M. The forecast indicates a -2.08% fall compared to CNMD last annual SG&A of $127.33M (Dec 23).
CONMED EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.05 | - | $0.45 | $0.06 | $0.87 | $1.51 | $-5.65 | $0.51 | $0.83 | $0.51 | $0.46 | $0.34 | $0.84 | $0.24 |
| Avg Forecast | - | - | - | - | $1.67 | $1.38 | $1.38 | $1.16 | $1.38 | $1.19 | $1.21 | $1.05 | $1.21 | $1.02 | $0.91 | $0.74 | $1.11 | $0.84 | $0.79 | $0.60 | $0.90 | $0.75 | $0.75 | $0.62 | $1.03 | $0.75 | $0.62 | $0.44 | $0.77 | $0.23 |
| High Forecast | - | - | - | - | $1.69 | $1.40 | $1.39 | $1.17 | $1.39 | $1.20 | $1.22 | $1.21 | $1.22 | $1.04 | $0.91 | $0.74 | $1.12 | $0.85 | $0.80 | $0.60 | $0.91 | $0.75 | $0.75 | $0.62 | $1.03 | $0.75 | $0.62 | $0.44 | $0.77 | $0.23 |
| Low Forecast | - | - | - | - | $1.65 | $1.36 | $1.36 | $1.14 | $1.36 | $1.18 | $1.19 | $0.90 | $1.19 | $1.01 | $0.91 | $0.74 | $1.10 | $0.83 | $0.78 | $0.59 | $0.89 | $0.75 | $0.75 | $0.62 | $1.03 | $0.75 | $0.62 | $0.44 | $0.77 | $0.23 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | - | 0.57% | 0.10% | 0.96% | 2.01% | -7.49% | 0.82% | 0.81% | 0.68% | 0.74% | 0.78% | 1.10% | 1.05% |
According to 3 Wall Street analysts, CONMED's projected average Quarter EPS for Mar 24 is $0.74, with a low estimate of $0.74 and a high estimate of $0.74. This represents a -29.73% decrease compared to CNMD previous annual EPS of $1.05 (Dec 23).
CONMED Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SGHT | Sight Sciences | - | - | 124.44% | Hold |
| LUNG | Pulmonx | - | - | 75.70% | Buy |
| ATEC | Alphatec | - | - | 68.39% | Buy |
| IRTC | iRhythm | - | - | 63.77% | Buy |
| SIBN | SI-BONE | - | - | 59.24% | Buy |
| KIDS | OrthoPediatrics | - | - | 50.34% | Buy |
| LIVN | LivaNova | - | - | 37.37% | Buy |
| CNMD | CONMED | - | - | 28.15% | Buy |
| OFIX | Orthofix Medical | - | - | 26.92% | |
| STE | STERIS | - | - | 19.75% | Buy |
| SRDX | Surmodics | - | - | 0.43% | Buy |
| ITGR | Integer | - | - | -0.08% | Buy |
| GMED | Globus Medical | - | - | -6.11% | Buy |
| GKOS | Glaukos | - | - | -14.28% | Buy |